{"entity":{"id":"nct04410796","kind":"trial","name":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers","aka":[],"tldr":"A phase 2 trial of osimertinib, carboplatin and pemetrexed in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","summary":"Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers is a phase 2, randomised interventional study registered as NCT04410796 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 571 participants, started 2020-05-28 and due to reach its primary completion in 2027-05. Interventions recorded: Osimertinib; Carboplatin; Pemetrexed. Conditions listed: Metastatic Non-small Cell Lung Cancer. Primary outcome: Determine the progression-free survival. Lung eligibility wording from the registry: \"* Biopsy proven metastatic non-small cell lung cancer, confirmed at enrolling institution\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT04410796","url":"https://clinicaltrials.gov/study/NCT04410796"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["cytotoxic-chemotherapy","kinase-inhibitors","platinum"],"targets":[],"drugs":["osimertinib","carboplatin","pemetrexed"],"companies":["astrazeneca","guardant-health"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04410796","phase":"2","setting":"A Phase 2 Randomized Study of Osimertinib Versus Osimertinib Plus Chemotherapy for Patients With Metastatic EGFR-Mutant Lung Cancers That Have Detectable EGFR-Mutant cfDNA in Plasma After Initiation of Osimertinib","sponsor":"Memorial Sloan Kettering Cancer Center","enrolled":571,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct04410796/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/"},{"id":"guardant-health","kind":"company","name":"Guardant Health","route":"/companies/guardant-health/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}